Literature DB >> 7989975

Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.

A M Samuel1, B Rajashekharrao.   

Abstract

UNLABELLED: The influence of cumulative absorbed dose, initial dose rate and mass of the remnant thyroid tissue on outcome of radioiodine treatment was assessed to determine an optimum value of absorbed dose and initial dose rate predictive of successful ablation.
METHODS: In 87 patients with thyroid carcinoma treated with 0.85-9.55 GBq (23-258 mCi) of 131I to ablate residual thyroid tissue, the cumulative absorbed dose and the initial dose rate were calculated. Following therapy, the parameters of radioactive iodine uptake and effective half-life were determined in each patient from the surface neck exposure rates measured using a beta/gamma exposure rate meter. Mass of the thyroid remnant was determined from rectilinear images after scatter correction obtained from phantom studies.
RESULTS: Sixty-eight patients showed complete ablation and 19 showed partial ablation of the thyroid remnant after radioiodine therapy. The cumulative absorbed doses delivered to the tissue in completely ablated and partially ablated groups were not significantly different (0.6 > p > 0.5). The initial dose rate delivered to the tissue in both groups, however, showed a significant difference (0.05 > p > 0.02). An initial dose rate of 3 Gy/hr or more completely ablated up to 5 g of tissue in 54 out of 62 patients (87.1%). Dose rate above 3 Gy/hr and cumulative doses above 300 Gy resulted in ablation in 50% of patients with more than 5 g of tissue.
CONCLUSION: In patients receiving 131I to ablate thyroid remnant, the initial dose rate and the tissue mass are determinants of successful treatment response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989975

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Seeking a radiobiological explanation for thyroid stunning.

Authors:  M Medvedec
Journal:  Eur J Nucl Med       Date:  2001-03

2.  Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.

Authors:  Deepa Rani; Sushma Kaisar; Sushma Awasare; Amit Abhyankar; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-01       Impact factor: 9.236

3.  Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer.

Authors:  V Oliynyk; O Epshtein; T Sovenko; M Tronko; R Elisei; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

4.  Measurement of the radioactive body burden in patients receiving iodine-131 treatment for carcinoma of the thyroid.

Authors:  R Ravichandran; S S Supe; U Jayasree; S Devaru
Journal:  Eur J Nucl Med       Date:  1997-04

5.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

6.  Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning.

Authors:  Elisa Caballero-Calabuig; Carmen Cano-Terol; Ramón Sopena-Monforte; Dolores Reyes-Ojeda; Pedro Abreu-Sánchez; José Ferrer-Rebolleda; Pablo Sopena-Novales; Carmen Plancha-Mansanet; Jesús Félix-Fontestad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

7.  Lesion-Wise Comparison of Pre-Therapy and Post-Therapy Effective Half-Life of Iodine-131 in Pediatric and Young Adult Patients with Differentiated Thyroid Cancer Undergoing Radioiodine Therapy.

Authors:  Praveen Kumar; Chandrasekhar Bal; Nishikant Avinash Damle; Sanjana Ballal; S N Dwivedi; Sandeep Agarwala
Journal:  Nucl Med Mol Imaging       Date:  2019-04-23

8.  Estimation of effective half life of clearance of radioactive Iodine (I) in patients treated for hyperthyroidism and carcinoma thyroid.

Authors:  R Ravichandran; Jp Binukumar; Amal Al Saadi
Journal:  Indian J Nucl Med       Date:  2010-04

Review 9.  Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.

Authors:  Mojtaba Ansari; Mostafa Rezaei Tavirani
Journal:  Iran J Pharm Res       Date:  2022-05-14       Impact factor: 1.962

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.